CryoPort Inc (NAS:CYRX)

$ 8.24 -0.06 (-0.72%) Market Cap: 410.27 Mil Enterprise Value: 404.73 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 71/100

Q3 2024 Cryoport Inc Earnings Call Transcript
Nov 07, 2024

$8.02

Earnings
Q2 2024 Cryoport Inc Earnings Call Transcript
Aug 06, 2024

$7.79 (+4.14%)

Earnings
Q1 2024 Cryoport Inc Earnings Call Transcript
May 07, 2024

$16.4 (+2.50%)

Earnings
Q4 2023 Cryoport Inc Earnings Call Transcript
Mar 12, 2024

$16.3 (-0.49%)

Earnings
Q3 2023 Cryoport Inc Earnings Call Transcript
Nov 08, 2023

$10.27 (-1.06%)

Earnings
Q2 2023 Cryoport Inc Earnings Call Transcript
Aug 09, 2023

$13.65 (+1.56%)

Earnings
Q1 2023 Cryoport Inc Earnings Call Transcript
May 04, 2023

$21.01 (+0.19%)

Earnings
Q4 2022 Cryoport Inc Earnings Call Transcript
Feb 23, 2023

$20.6 (+4.52%)

Earnings
Q3 2022 Cryoport Inc Earnings Call Transcript
Nov 03, 2022

$26.49 (-2.61%)

Earnings
Q2 2022 Cryoport Inc Earnings Call Transcript
Aug 04, 2022

$36.93 (+0.11%)

Earnings
Q1 2022 Cryoport Inc Earnings Call Transcript
May 05, 2022

$24.17 (-6.97%)

Earnings
Q4 2021 Cryoport Inc Earnings Call Transcript
Feb 24, 2022

$33.45 (+4.69%)

Earnings
Cryoport Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Q3 2021 Cryoport Inc Earnings Call Transcript
Nov 04, 2021

$83.29 (+1.50%)

Earnings
Q2 2021 Cryoport Inc Earnings Call Transcript
Aug 05, 2021

$65.15 (+3.54%)

Earnings
Q1 2021 Cryoport Inc Earnings Call Transcript
May 04, 2021

$55.22 (-2.27%)

Earnings
Q4 2020 Cryoport Inc Earnings Call Transcript
Mar 01, 2021

$62.49 (+5.13%)

Earnings
Q3 2020 Cryoport Inc Earnings Call Transcript
Nov 05, 2020

$43.25 (-0.51%)

Earnings
Chart Industries Inc to Divest Cryobiological Products Business to Cryoport Inc Conference Call Transcript
Aug 25, 2020
Cryoport Inc to Acquire MVE Biological Solutions from Chart Industries Conference Call Transcript
Aug 25, 2020
CRYOPDP, Cryoport, Inc. - M&A Call Transcript
Aug 21, 2020
Q2 2020 Cryoport Inc Earnings Call Transcript
Aug 06, 2020

$34.98 (+2.13%)

Earnings
Cryoport, Inc. - Special Call Transcript
Jul 29, 2020
Q1 2020 Cryoport Inc Earnings Call Transcript
May 07, 2020

$20.64 (+1.47%)

Earnings
Q4 2019 Cryoport Inc Earnings Call Transcript
Mar 05, 2020

$17.37 (-2.63%)

Earnings
Q3 2019 Cryoport Inc Earnings Call Transcript
Nov 07, 2019

$14.28 (+3.18%)

Earnings
Q2 2019 Cryoport Inc Earnings Call Transcript
Aug 08, 2019

$20.18 (+4.18%)

Earnings
Q1 2019 Cryoport Inc Earnings Call Transcript
May 02, 2019

$14.35 (+0.99%)

Earnings
Q4 2018 Cryoport Inc Earnings Call Transcript
Mar 07, 2019

$10.6 (-2.12%)

Earnings

Cryoport, Inc. - Special Call Transcript

Jul 29, 2020 / 03:00PM GMT

Release Date Price: $32.71 (-0.52%)

Transcript 10-Q8-K

Agnes Shanley;MJH Associates;Senior Editor

Hello, everyone. Welcome to today's Editors' Series broadcast, Cell and Gene Therapies: Laying the Foundation for a New Supply Chain. This is Agnes Shanley, Senior Editor of BioPharm International and Pharmaceutical Technology, and I'll be moderating today's event.

This webcast will explore some of the challenges presented by scaling up cell and gene therapies and how a vein-to-vein supply chain partnership is benefiting them.

It is presented by BioPharm International and Pharmaceutical Technology in conjunction with INTERPHEX, the premier pharmaceutical, biotechnology and device development and manufacturing event, to "experience science through commercialization" through exhibits, networking and conferences to leverage quality, efficiency and cost effectiveness. INTERPHEX will take place from April 20 through the 22nd 2021, in New York City. And sponsored by Eurofins BioPharma Product Testing, Honeywell and Lonza Pharma & Biotech. Before we begin, some brief messages from the program sponsors.

Eurofins

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.